ivWatch, LLC

ivWatch, LLC ivWatch, LLC is medical device and biosensor company looking to improve patient safety during IV use

ivWatch, LLC is a medical device company focused on improving the safety and effectiveness of intravenous (IV) therapy. IV therapy is a basic yet critical component of care in hospital and outpatient settings, but it has a high failure rate. Continuous monitors exist to keep track of patients’ heart, blood oxygen levels and pulse rates. Until now, no technology has been available to continuously monitor the health of a patient’s IV site, and whether drugs or fluids are being delivered through the vein or leaking into the tissue. The ivWatch Model 400 is a FDA-cleared device to help clinicians monitor the status of a patient’s IV to aid in the early detection of peripheral IV infiltrations and extravasations. Through the use of non-invasive sensor technology, the ivWatch Model 400 can help reduce potentially serious medication dosing errors and associated patient harm from infiltration events. A continuously monitored peripheral IV also offers an alternative to more intrusive vascular access devices when medically indicated. Use of these devices has increased, but can also pose significant risk of harm to patients and greater cost and liability for hospitals. ivWatch has the potential to transform IV therapy by improving patient care and safety, and offering health care providers a much-needed, reliable and cost-effective solution for continuously monitoring peripheral IVs.

This fall, ivWatch is putting IV safety on centerstage. Meet with our team to uncover the hidden financial and clinical ...
09/10/2025

This fall, ivWatch is putting IV safety on centerstage.

Meet with our team to uncover the hidden financial and clinical burden of IV extravasations. From patient safety and quality improvement programs to vascular access to people leaders, we’re showcasing how early detection and continuous monitoring can reduce the severity of IV harm and protect patients worldwide.

Join us at these events to see how proactive technology is reshaping the approach to patient safety.

Read more about the activations and book a time to meet with us: https://www.ivwatch.com/2025/09/09/confronting-the-hidden-financial-and-clinical-dangers-in-iv-therapy-ivwatch-showcases-solution-for-iv-safety-at-leading-global-conferences-and-pediatric-webinar/

It's time to tackle IV complications before they escalate. Hospitals are taking a stance and pioneering technology to he...
09/09/2025

It's time to tackle IV complications before they escalate.

Hospitals are taking a stance and pioneering technology to help reduce the severity of infusion-related extravasation injuries — they’re setting a new standard for patient safety.

Curious about implementing continuous patient monitoring in your hospital?

Click here to book a demo: https://www.ivwatch.com/request-a-demo/

Just in: New research findings on IV safety in the NICU.Hear firsthand from neonatal vascular access expert Roland VanRe...
09/08/2025

Just in: New research findings on IV safety in the NICU.

Hear firsthand from neonatal vascular access expert Roland VanRens as he shares results from three neonatal studies—including a newly published retrospective cohort of 32,000+ IV insertions analyzed.
Discover how standard observation often misses early warning signs of PIVIEs, and how continuous optical monitoring dramatically reduces severity—protecting the most vulnerable patients.

Learn how pairing early detection with the 7 Rights framework can reshape outcomes in neonatal care.

𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟭𝟲, 𝟮𝟬𝟮𝟱 𝗮𝘁 𝟭𝟮:𝟬𝟬𝗣𝗠 𝗘𝗦𝗧

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗡𝗼𝘄:
0c0515bd-7996-4f6a-a1e9-a0ee5e65a087@e4793c48-5702-4a04-a353-7a4fc14d3f1c" rel="ugc" target="_blank">https://events.teams.microsoft.com/event/0c0515bd-7996-4f6a-a1e9-a0ee5e65a087@e4793c48-5702-4a04-a353-7a4fc14d3f1c

Vascular access teams are uniquely positioned to drive the next wave of patient safety. With more vasopressors infused p...
09/04/2025

Vascular access teams are uniquely positioned to drive the next wave of patient safety. With more vasopressors infused peripherally and high-risk drugs being administered outside central lines, vulnerable patients face greater risk of IV complications.

Touch–look–compare IV assessments are not enough. If you’re waiting for visible harm to appear, it’s too late. Are you tracking and grading PIVIEs—and measuring their true clinical, financial and pathway ramifications of infiltration and extravasation injuries on your patients?

Join us at AVA 2025, booth #607, to see how continuous surveillance monitoring detects infiltrations early, reduces injury severity, and raises the standard for prevention-first IV therapy.

Book a meeting: https://lnkd.in/e2J7RyRA

Melissa Williams went into surgery expecting relief. Instead, she left with a life-changing injury—the result of an IV e...
08/25/2025

Melissa Williams went into surgery expecting relief.

Instead, she left with a life-changing injury—the result of an IV extravasation.

What followed the routine procedure?

• 25+ surgeries
• Ring finger amputation
• Lost years of motherhood and mobility

All from a routine IV.

All because many extravasations happen silently, until it’s too late.

At ivWatch, we’re giving patients like Melissa a voice. We’re exposing the silent risk and delivering early detection technology that prompts clinicians to act before it’s too late.

Read more: https://www.ivwatch.com/2024/10/03/a-preventable-iv-injury-changed-an-artists-life-forever/

By age five, Jack had endured eight major surgeries and more IVs than anyone could count. Jack was able to verbalize his...
08/21/2025

By age five, Jack had endured eight major surgeries and more IVs than anyone could count. Jack was able to verbalize his IV pain saying “It hurts,” but was dismissed by clinicians when the standard TLC (Look-Touch-Compare) showed no signs of an infiltration.

It wasn’t until the area around his IV swelled to a golf ball size did the clinicians act, but by then, the damage was already done—and irreversible.

IV injuries like Jack’s happen far too often in children. They can go undetected until swelling, blistering, or tissue damage appears—long after the harm is done.

These injuries are preventable with IV surveillance technology.

Learn more here: https://www.ivwatch.com/2020/06/04/patient-voices-jack/

When it comes to our most vulnerable patients, early detection is everything.IV infiltration injuries in neonates can de...
08/18/2025

When it comes to our most vulnerable patients, early detection is everything.

IV infiltration injuries in neonates can develop silently—and escalate quickly. That’s why real-time 24/7 monitoring matters.


A new BMJ-published study showed that the use of ivWatch optical sensor technology significantly reduced the severity of peripheral IV infiltrations and extravasations (PIVIE) in NICU patients.

In fact, severe PIVIE cases plunged 14.3x when ivWatch was added to standard care.

ivWatch monitors IV sites for fluid leaking before visible signs appear—allowing clinicians to act fast and prevent harm.

🔗 https://www.ivwatch.com/2025/07/09/ivwatch-technology-linked-to-major-reduction-in-severe-iv-injuries-in-newborns-over-four-year-study/

Are you documenting all infiltration and extravasation events and taking it one step further by grading the injuries? Un...
08/13/2025

Are you documenting all infiltration and extravasation events and taking it one step further by grading the injuries?

Understanding your data is the first step to reducing harm.

Learn how to apply standardized grading scales such as the IEGS Swelling Scale created by Cincinnati Children's or Infusion Nurses Society
Infiltration scale and how continuous monitoring with ivWatch can help keep swelling reduced to less than 15% and turn 3s and 4s into 1s and 2s.

Read the full blog: https://lnkd.in/egsd-Yyx

ivWatch is on a global mission to elevate infusion safety — and we’re proud to partner with Medlands Medical to bring th...
08/11/2025

ivWatch is on a global mission to elevate infusion safety — and we’re proud to partner with Medlands Medical to bring this vision to life.

Together, we’re working alongside hospitals and healthcare leaders to enhance IV therapy practices, align with institutional safety goals, and reduce avoidable patient harm through advanced infiltration detection.

Every visit is a step toward empowering nurses, improving clinical outcomes, and setting a new benchmark for IV care.

This is more than innovation — it’s a new standard.

In NICUs, up to 80% of IVs fail due to infiltration and extravasation. These aren’t just complications—they're preventab...
08/07/2025

In NICUs, up to 80% of IVs fail due to infiltration and extravasation. These aren’t just complications—they're preventable injuries with long-term consequences, from scarring and loss of limb function to lifelong psychological damages.

Roland VanRens has seen firsthand how continuous surveillance with ivWatch transforms care. With real-time alerts from optical sensors, clinicians no longer have to rely solely on visual cues or subjective assessments.

Technology fills the critical gap—detecting infiltrations before they become visible, before tissue damage manifests.

This isn’t optional care—it’s essential care.

Read more (page 15-17): https://lnkd.in/e3QNmF6K

IV infiltrations aren't just complications—they’re drug-dosing errors. When medication or fluid leaks outside the vein a...
08/06/2025

IV infiltrations aren't just complications—they’re drug-dosing errors. When medication or fluid leaks outside the vein and into surrounding tissue, the intended therapy is no longer delivered into the bloodstream and creates uncertainty on the exact dose received, which can delay treatment or cause serious harm.

The reality:
• Up to 58% of peripheral IVs fail during therapy, often due to infiltration or extravasation.
• These events can go undetected for hours, especially in non-verbal or critically ill patients.
• In vulnerable populations—like neonates, pediatrics, and oncology—even a few drops of misplaced medication can cause permanent tissue damage or nerve injury.

𝘏𝘦𝘭𝘮 𝘙𝘌 𝘦𝘵 𝘢𝘭. (2015) "𝘈𝘤𝘤𝘦𝘱𝘵𝘦𝘥 𝘣𝘶𝘵 𝘶𝘯𝘢𝘤𝘤𝘦𝘱𝘵𝘢𝘣𝘭𝘦: 𝘱𝘦𝘳𝘪𝘱𝘩𝘦𝘳𝘢𝘭 𝘐𝘝 𝘤𝘢𝘵𝘩𝘦𝘵𝘦𝘳 𝘧𝘢𝘪𝘭𝘶𝘳𝘦"

ivWatch is visiting hospitals who share a commitment to proactive patient care and IV therapy excellence. These teams ar...
08/04/2025

ivWatch is visiting hospitals who share a commitment to proactive patient care and IV therapy excellence.

These teams are focused on preventing complications, not just reacting to them. By embracing early detection, they're setting a higher standard for infusion safety.

Together, we’re helping to prevent complications before they become harm. Advancing IV therapy starts with prevention.

Address

700 Tech Center Parkway, Suite 300
Newport News, VA
23606

Opening Hours

Monday 8:30am - 6pm
Tuesday 8:30am - 6pm
Wednesday 8:30am - 6pm
Thursday 8:30am - 6pm
Friday 8:30am - 6pm

Website

Alerts

Be the first to know and let us send you an email when ivWatch, LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ivWatch, LLC:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

ivWatch, LLC is a medical device company focused on improving the safety and effectiveness of intravenous (IV) therapy. IV therapy is a basic yet critical component of care in hospital and outpatient settings, but it has a high failure rate. Continuous monitors exist to keep track of patients’ heart, blood oxygen levels and pulse rates. Until now, no technology has been available to continuously monitor the health of a patient’s IV site, and whether drugs or fluids are being delivered through the vein or leaking into the tissue. The ivWatch Model 400 is a FDA-cleared device to help clinicians monitor the status of a patient’s IV to aid in the early detection of peripheral IV infiltrations and extravasations. Through the use of non-invasive sensor technology, the ivWatch Model 400 can help reduce potentially serious medication dosing errors and associated patient harm from infiltration events. A continuously monitored peripheral IV also offers an alternative to more intrusive vascular access devices when medically indicated. Use of these devices has increased, but can also pose significant risk of harm to patients and greater cost and liability for hospitals. ivWatch has the potential to transform IV therapy by improving patient care and safety, and offering health care providers a much-needed, reliable and cost-effective solution for continuously monitoring peripheral IVs.